share_log

民生证券4月25日发布研报称，给予九洲药业（603456.SH）推荐评级。评级理由主要包括：1）诺欣妥一季度全球销售提速增长，CDMO订单稳健提升；2）多肽、小核酸等新兴业务快速成长，战略布局海外CRO平台提高客户粘性。（每日经济新闻）

Minsheng Securities released a research report on April 25 stating that it gave Jiuzhou Pharmaceutical (603456.SH) a recommended rating. The main reasons for the rating include: 1) Noxintol's global sales increased rapidly in the first quarter, and CDMO o

Zhitong Finance ·  Apr 25 10:56
Minsheng Securities released a research report on April 25 stating that it gave Jiuzhou Pharmaceutical (603456.SH) a recommended rating. The main reasons for the rating include: 1) Noxintol's global sales increased rapidly in the first quarter, and CDMO orders increased steadily; 2) emerging businesses such as peptides and small nucleic acids grew rapidly, and the strategic layout of overseas CRO platforms increased customer stickiness. (Mainichi Keizai Shimbun)

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment